This single-center case series describes six patients with small iris or iridociliary melanomas treated with a high-dose-rate yttrium-90 plaque in a single outpatient procedure. Treatment times averaged under ten minutes, and no serious ocular side effects or metastases were seen over about 16 months of follow-up. Yttrium here is a beta-emitting radioisotope used as a radiation source.
Key numbers
This paper reports no numerical findings relevant to yttrium exposure.
Methods (brief)
Clinical case series with tumor staging, slit-lamp and gonio photography, and high-frequency ultrasound to track tumor size and side effects.
Evidence fitness
Off-topic for dietary exposure: a radiotherapy case series that does not support dietary exposure or toxicity claims for stable yttrium.
Limitations
Six patients and short follow-up. The author discloses patents, royalties, stock and executive roles in the company that holds the applicator patent.
Related evidence
Update history
No substantive edit history is available in this build. The full commit record is available in git.